

Proof-of-concept study demonstrating the pathogenicity
directed to domain I of β 2-glycoprotein I in a mouse model of
antibody-induced thrombosis

Rheumatology

54, 722-727

DOI: [10.1093/rheumatology/keu360](https://doi.org/10.1093/rheumatology/keu360)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Antibodies to domain I of β_2 -glycoprotein I and IgA antiphospholipid antibodies in patients with β_2 -glycoprotein I antibody positive antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 317-319.	0.9	42
2	Recent advances in understanding antiphospholipid syndrome. <i>F1000Research</i> , 2016, 5, 2908.	1.6	12
3	Measuring IgA Anti- β_2 -Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. <i>PLoS ONE</i> , 2016, 11, e0156407.	2.5	66
4	Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome. <i>Scientific Reports</i> , 2016, 6, 23839.	3.3	23
5	Current status and future prospects for the treatment of antiphospholipid syndrome. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 927-935.	3.0	8
6	The association between IgG and IgM antibodies against cardiolipin, β_2 -glycoprotein I and Domain I of β_2 -glycoprotein I with disease profile in patients with multiple sclerosis. <i>Molecular Immunology</i> , 2016, 75, 161-167.	2.2	14
7	Is leukocyte tissue factor the key to venous thrombosis in antiphospholipid syndrome?. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1008-1010.	3.8	2
8	Single test isolated lupus anticoagulant positivity is associated with increased plasma levels of inflammatory markers and dyslipidemia. <i>Lupus</i> , 2016, 25, 241-247.	1.6	6
9	Delineating the deranged immune system in the antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2016, 15, 50-60.	5.8	56
11	Pathogenesis and management of antiphospholipid syndrome. <i>British Journal of Haematology</i> , 2017, 178, 181-195.	2.5	80
12	Antiphospholipid antibody-induced cellular responses depend on epitope specificity : implications for treatment of antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2367-2376.	3.8	25
13	Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by IgG From Patients With Lupus and/or Antiphospholipid Syndrome. <i>Scientific Reports</i> , 2017, 7, 10788.	3.3	7
14	Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances. <i>Nature Reviews Rheumatology</i> , 2017, 13, 548-560.	8.0	153
15	Mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 334-341.	3.3	41
16	In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 655-667.	5.6	166
17	Pathophysiological insights into the antiphospholipid syndrome. <i>Hamostaseologie</i> , 2017, 37, 202-207.	1.9	3
18	Oxidation of β_2 -glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. <i>PLoS ONE</i> , 2017, 12, e0186513.	2.5	8
19	Detection of Anti-Domain I β_2 Glycoprotein I Antibodies as New Potential Target in Antiphospholipid Syndrome Diagnosis. <i>Journal of Hematology & Thromboembolic Diseases</i> , 2017, 05, .	0.1	1

#	ARTICLE	IF	CITATIONS
20	Antiphospholipid syndrome. <i>Nature Reviews Disease Primers</i> , 2018, 4, 17103.	30.5	233
21	Thrombophilia Caused by Beta2-Glycoprotein I Deficiency: In Vitro Study of a Rare Mutation in APOH Gene. <i>Current Medical Science</i> , 2018, 38, 379-385.	1.8	6
22	Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK. <i>Cell Death and Disease</i> , 2018, 8, e2549-e2549.	6.3	17
23	Mechanisms of Cellular Activation in the Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 483-492.	2.7	20
24	The Significance of Antibodies against Domain I of Beta-2 Glycoprotein I in Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 458-465.	2.7	12
25	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2018, 9, 2413.	4.8	14
26	The clinical value of assays detecting antibodies against domain I of β 2-glycoprotein I in the antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018, 17, 1210-1218.	5.8	27
27	Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I. <i>Frontiers in Immunology</i> , 2018, 9, 2244.	4.8	11
28	Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome. <i>Frontiers in Immunology</i> , 2018, 9, 969.	4.8	47
29	Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 860-866.	3.4	20
30	Environmental Triggers of Autoreactive Responses: Induction of Antiphospholipid Antibody Formation. <i>Frontiers in Immunology</i> , 2019, 10, 1609.	4.8	39
31	Pathogenic Autoreactive T and B Cells Cross-React with Mimotopes Expressed by a Common Human Gut Commensal to Trigger Autoimmunity. <i>Cell Host and Microbe</i> , 2019, 26, 100-113.e8.	11.0	109
32	Anti-domain 1 of beta2-glycoprotein I aids risk stratification in lupus anticoagulant-positive patients. <i>Clinical and Experimental Medicine</i> , 2019, 19, 339-345.	3.6	6
33	Pathogenesis of Antiphospholipid Antibody Syndrome. , 2019, , 324-337.		3
34	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 93-106.	5.8	101
35	The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. <i>Blood Reviews</i> , 2020, 39, 100610.	5.7	85
37	Anti- β 2GPI domain 1 antibodies stratify high risk of thrombosis and late pregnancy morbidity in a large cohort of Chinese patients with antiphospholipid syndrome. <i>Thrombosis Research</i> , 2020, 185, 142-149.	1.7	19
38	Detection of anti-domain I antibodies by chemiluminescence enables the identification of high-risk antiphospholipid syndrome patients: A multicenter multiplatform study. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 463-478.	3.8	20

#	ARTICLE	IF	CITATIONS
39	High Prevalence of Acquired Thrombophilia Without Prognosis Value in Patients With Coronavirus Disease 2019. <i>Journal of the American Heart Association</i> , 2020, 9, e017773.	3.7	39
40	Molecular Mechanisms of Antiphospholipid Antibodies and Their Paradoxical Role in the Pathogenesis of Seronegative APS. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8411.	4.1	21
41	The Weight of IgA Anti- β 2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8972.	4.1	23
42	16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. <i>Lupus</i> , 2020, 29, 1601-1615.	1.6	27
43	Anti-phospholipid antibodies and reproductive failures. <i>American Journal of Reproductive Immunology</i> , 2021, 85, e13258.	1.2	13
44	Pathogenesis of antiphospholipid syndrome. , 2021, , 555-564.		0
45	Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding. <i>Scientific Reports</i> , 2021, 11, 4542.	3.3	3
46	Understanding the Pathophysiology of Thrombotic APS through Animal Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2588.	4.1	9
47	B cells in primary antiphospholipid syndrome: Review and remaining challenges. <i>Autoimmunity Reviews</i> , 2021, 20, 102798.	5.8	10
48	Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study. <i>EclinicalMedicine</i> , 2021, 39, 101070.	7.1	21
49	The pivotal role of endothelial protein C receptor for antiphospholipid antibody-mediated pathologies. <i>Rheumatology</i> , 2022, 61, 883-885.	1.9	1
50	Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis. , 2017, , 77-116.		3
51	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests. , 2017, , 171-187.		3
52	Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target. <i>JCI Insight</i> , 2017, 2, .	5.0	75
53	Natural Proteins Involved in Antiphospholipid Syndrome. , 2017, , 15-27.		1
54	Effects of anti-beta 2-glycoprotein 1 antibodies and its association with pregnancy-related morbidity in antiphospholipid syndrome. <i>American Journal of Reproductive Immunology</i> , 2022, 87, e13509.	1.2	9
58	Antibodies to domain I β 2-glycoprotein 1 in patients with antiphospholipid syndrome and systemic lupus erythematosus. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 353-359.	1.0	1
59	Anti-phosphatidylserine/prothrombin complex antibodies (aPS/PT) increase the risk for thrombosis based on lupus anticoagulant positivity. <i>Clinical Biochemistry</i> , 2023, 112, 17-23.	1.9	2

#	ARTICLE	IF	CITATIONS
60	Evolution of Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 295-304.	2.7	4
61	Role of Î²2â€¢glycoprotein I in the pathogenesis of the antiphospholipid syndrome. <i>Rheumatology & Autoimmunity</i> , 0, , .	0.8	0
63	Anti-Î²2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China. <i>Lupus Science and Medicine</i> , 2023, 10, e000924.	2.7	0
64	Antibodies to Domain I Î²2-Glycoprotein 1 in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus. <i>Doklady Biochemistry and Biophysics</i> , 2023, 511, 219-226.	0.9	0
65	16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome laboratory diagnostics and trends. <i>Lupus</i> , 2023, 32, 1625-1636.	1.6	1
67	Viewpoint: The value of non-criteria antiphospholipid antibodies. <i>Rheumatology</i> , 2024, 63, SI64-SI71.	1.9	1